Kisspeptin-54 Levels are increased in Patients with Colorectal Cancer

World Journal of Surgery, 05/24/2012

The results reveal that plasma Kisspeptin–54 measurement could be a useful diagnostic and prognostic parameter for CRC. Further prospective evaluation is needed to validate these findings and to establish the clinical usefulness of Kisspeptin–54 for CRC diagnostics.

Methods

  • Plasma Kisspeptin–54 levels were quantified using enzyme–immunoassay (EIA) kits from blood samples of 81 patients with CRC at their initial staging and 59 age–matched healthy controls.

Results

  • Plasma Kisspeptin–54 levels were significantly higher in CRC patients (86.2 ± 20.5) than in controls (49 ± 12.7; p < 0.005).
  • The cutoff value for Kisspeptin–54 detection was determined as 46 ng/ml, and area under curve (AUC) value was 0.766 with sensitivity 63 %, specificity 81.4 %, positive predictive value 82.2 %, negative predictive value 61.5 %, positive likelihood ratio 3.38, and negative likelihood ratio 0.46.
  • Increased plasma Kisspeptin–54 levels were significantly correlated with nodal involvement of CRC (Spearman, rs = 0.345, p = 0.002).
  • Kisspeptin–54 was also found to be an independent predictive marker for lymph node metastases of CRC (p = 0; Exp(B): 2.053; 95 % CI, 1.255–2.851).

Print Article Summary Cat 2 CME Report